|
1
|
Centeno PP, Pavet V and Marais R: The
journey from melanocytes to melanoma. Nat Rev Cancer. 23:372–390.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zoghlami A, Roussel F, Sabourin JC, Kuhn
JM, Marie JP, Dehesdin D and Choussy O: BRAF mutation in papillary
thyroid carcinoma: predictive value for long-term prognosis and
radioiodine sensitivity. Eur Ann Otorhinolaryngol Head Neck Dis.
131:7–13. 2014. View Article : Google Scholar
|
|
5
|
Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li
Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI and Rosen
N: BRAF Mutants Evade ERK-dependent feedback by different
mechanisms that determine their sensitivity to pharmacologic
inhibition. Cancer Cell. 28:370–383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanrahan AJ, Chen Z, Rosen N and Solit DB:
BRAF-a tumour-agnostic drug target with lineage-specific
dependencies. Nat Rev Clin Oncol. 21:224–247. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Holderfield M, Deuker MM, McCormick F and
McMahon M: Targeting RAF kinases for cancer therapy: BRAF-mutated
melanoma and beyond. Nat Rev Cancer. 14:455–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng L, Lopez-Beltran A, Massari F,
MacLennan GT and Montironi R: Molecular testing for BRAF mutations
to inform melanoma treatment decisions: A move toward precision
medicine. Mod Pathol. 31:24–38. 2018. View Article : Google Scholar :
|
|
9
|
Robertson BM, Fane ME, Weeraratna AT and
Rebecca VW: Determinants of resistance and response to melanoma
therapy. Nat Cancer. 5:964–982. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsai J, Lee JT, Wang W, Zhang J, Cho H,
Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al: Discovery of
a selective inhibitor of oncogenic B-Raf kinase with potent
antimelanoma activity. Proc Natl Acad Sci USA. 105:3041–3046. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bollag G, Hirth P, Tsai J, Zhang J,
Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al:
Clinical efficacy of a RAF inhibitor needs broad target blockade in
BRAF-mutant melanoma. Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sondergaard JN, Nazarian R, Wang Q, Guo D,
Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM,
et al: Differential sensitivity of melanoma cell lines with
BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl
Med. 8:392010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tap WD, Gong KW, Dering J, Tseng Y,
Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, et
al: Pharmacodynamic characterization of the efficacy signals due to
selective BRAF inhibition with PLX4032 in malignant melanoma.
Neoplasia. 12:637–649. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee JT, Li L, Brafford PA, van den Eijnden
M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G
and Herlyn M: PLX4032, a potent inhibitor of the B-Raf V600E
oncogene, selectively inhibits V600E-positive melanomas. Pigment
Cell Melanoma Res. 23:820–827. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Halaban R, Zhang W, Bacchiocchi A, Cheng
E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y and
Sznol M: PLX4032, a selective BRAF(V600E) kinase inhibitor,
activates the ERK pathway and enhances cell migration and
proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res.
23:190–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Joseph EW, Pratilas CA, Poulikakos PI,
Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A,
et al: The RAF inhibitor PLX4032 inhibits ERK signaling and tumor
cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad
Sci USA. 107:14903–14908. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Flaherty K, Puzanov I, Sosman J, Kim K,
Ribas A, McArthur G, Lee RJ, Grippo JF, Nolop K and Chapman P:
Phase I study of PLX4032: Proof of concept for V600E BRAF mutation
as a therapeutic target in human cancer. J Clin Oncol.
27(15_suppl): S90002009. View Article : Google Scholar
|
|
19
|
Kim G, McKee AE, Ning YM, Hazarika M,
Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, et al:
FDA approval summary: Vemurafenib for treatment of unresectable or
metastatic melanoma with the BRAFV600E mutation. Clin Cancer Res.
20:4994–5000. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chapman PB, Robert C, Larkin J, Haanen JB,
Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, et
al: Vemurafenib in patients with BRAFV600 mutation-positive
metastatic melanoma: Final overall survival results of the
randomized BRIM-3 study. Ann Oncol. 28:2581–2587. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Stellwagen JC, Adjabeng GM, Arnone MR,
Dickerson SH, Han C, Hornberger KR, King AJ, Mook RA Jr, Petrov KG,
Rheault TR, et al: Development of potent B-RafV600E inhibitors
containing an arylsulfonamide headgroup. Bioorg Med Chem Lett.
21:4436–4440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
King AJ, Arnone MR, Bleam MR, Moss KG,
Yang J, Fedorowicz KE, Smitheman KN, Erhardt JA, Hughes-Earle A,
Kane-Carson LS, et al: Dabrafenib; preclinical characterization,
increased efficacy when combined with trametinib, while BRAF/MEK
tool combination reduced skin lesions. PLoS One. 8:e675832013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laquerre S, Arnone M, Moss K, Yang J,
Fisher K, Kane-Carson LS, Smitheman K, Ward J, Heidrich B, Rheault
T, et al: Abstract B88: A selective Raf kinase inhibitor induces
cell death and tumor regression of human cancer cell lines encoding
B-RafV600E mutation. Mol Cancer Ther. 8(12_Suppl): B882009.
View Article : Google Scholar
|
|
25
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schilling B, Sondermann W, Zhao F,
Griewank KG, Livingstone E, Sucker A, Zelba H, Weide B, Trefzer U,
Wilhelm T, et al: Differential influence of vemurafenib and
dabrafenib on patients' lymphocytes despite similar clinical
efficacy in melanoma. Ann Oncol. 25:747–753. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ascierto PA, Minor D, Ribas A, Lebbe C,
O'Hagan A, Arya N, Guckert M, Schadendorf D, Kefford RF, Grob JJ,
et al: Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib
(GSK2118436) in patients with metastatic melanoma. J Clin Oncol.
31:3205–3211. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Park E, Rawson S, Li K, Kim BW, Ficarro
SB, Pino GG, Sharif H, Marto JA, Jeon H and Eck MJ: Architecture of
autoinhibited and active BRAF-MEK1-14-3-3 complexes. Nature.
575:545–550. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hatzivassiliou G, Song K, Yen I,
Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor
SL, Vigers G, et al: RAF inhibitors prime wild-type RAF to activate
the MAPK pathway and enhance growth. Nature. 464:431–435. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Poulikakos PI, Zhang C, Bollag G, Shokat
KM and Rosen N: RAF inhibitors transactivate RAF dimers and ERK
signalling in cells with wild-type BRAF. Nature. 464:427–430. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Heidorn SJ, Milagre C, Whittaker S, Nourry
A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer
CJ, Pritchard C and Marais R: Kinase-dead BRAF and oncogenic RAS
cooperate to drive tumor progression through CRAF. Cell.
140:209–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gilmartin AG, Bleam MR, Groy A, Moss KG,
Minthorn EA, Kulkarni SG, Rominger CM, Erskine S, Fisher KE, Yang
J, et al: GSK1120212 (JTP-74057) is an inhibitor of MEK activity
and activation with favorable pharmacokinetic properties for
sustained in vivo pathway inhibition. Clin Cancer Res. 17:989–1000.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yoshida T, Kakegawa J, Yamaguchi T,
Hantani Y, Okajima N, Sakai T, Watanabe Y and Nakamura M:
Identification and characterization of a novel chemotype MEK
inhibitor able to alter the phosphorylation state of MEK1/2.
Oncotarget. 3:1533–1545. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Falchook GS, Lewis KD, Infante JR, Gordon
MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT,
et al: Activity of the oral MEK inhibitor trametinib in patients
with advanced melanoma: A phase 1 dose-escalation trial. Lancet
Oncol. 13:782–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Flaherty KT, Robert C, Hersey P, Nathan P,
Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, et
al: Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med. 367:107–114. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim KB, Kefford R, Pavlick AC, Infante JR,
Ribas A, Sosman JA, Fecher LA, Millward M, McArthur GA, Hwu P, et
al: Phase II study of the MEK1/MEK2 inhibitor Trametinib in
patients with metastatic BRAF-mutant cutaneous melanoma previously
treated with or without a BRAF inhibitor. J Clin Oncol. 31:482–489.
2013. View Article : Google Scholar
|
|
37
|
Imani S, Roozitalab G, Emadi M, Moradi A,
Behzadi P and Jabbarzadeh Kaboli P: The evolution of BRAF-targeted
therapies in melanoma: Overcoming hurdles and unleashing novel
strategies. Front Oncol. 14:15041422024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Flaherty KT, Infante JR, Daud A, Gonzalez
R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N,
et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600
mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar
|
|
40
|
Robert C, Grob JJ, Stroyakovskiy D,
Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V,
Schachter J, Garbe C, Bondarenko I, et al: Five-Year outcomes with
dabrafenib plus trametinib in metastatic melanoma. N Engl J Med.
381:626–636. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Combined BRAF and MEK inhibition versus BRAF
inhibition alone in melanoma. N Engl J Med. 371:1877–1888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen G, McQuade JL, Panka DJ, Hudgens CW,
Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A,
et al: Clinical, molecular, and immune analysis of
dabrafenib-trametinib combination treatment for BRAF
inhibitor-refractory metastatic melanoma: A phase 2 clinical trial.
JAMA Oncol. 2:1056–1064. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rosen LS, LoRusso P, Ma WW, Goldman JW,
Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, et al: A
first-in-human phase I study to evaluate the MEK1/2 inhibitor,
cobimetinib, administered daily in patients with advanced solid
tumors. Invest New Drugs. 34:604–613. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Larkin J, Ascierto PA, Dreno B, Atkinson
V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas
L, et al: Combined vemurafenib and cobimetinib in BRAF-mutated
melanoma. N Engl J Med. 371:1867–1876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ascierto PA, McArthur GA, Dreno B,
Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L,
Stroyakovskiy D, Thomas L, et al: Cobimetinib combined with
vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM):
updated efficacy results from a randomised, double-blind, phase 3
trial. Lancet Oncol. 17:1248–1260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
de la Cruz-Merino L, Di Guardo L, Grob JJ,
Venosa A, Larkin J, McArthur GA, Ribas A, Ascierto PA, Evans JTR,
Gomez-Escobar A, et al: Clinical features of serous retinopathy
observed with cobimetinib in patients with BRAF-mutated melanoma
treated in the randomized coBRIM study. J Transl Med. 15:1462017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ascierto PA, Dreno B, Larkin J, Ribas A,
Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L,
et al: 5-year outcomes with cobimetinib plus vemurafenib in
BRAFV600 mutation-positive advanced melanoma: Extended follow-up of
the coBRIM study. Clin Cancer Res. 27:5225–5235. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shirley M: Encorafenib and binimetinib:
First global approvals. Drugs. 78:1277–1284. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Stuart DD, Li N, Poon DJ, Aardalen K,
Kaufman S, Merritt H, Salangsang F, Lorenzana E, Li A, Ghoddusi M,
et al: Abstract 3790: Preclinical profile of LGX818: A potent and
selective RAF kinase inhibitor. Cancer Res. 72(8_Suppl): S37902012.
View Article : Google Scholar
|
|
50
|
Huang T, Karsy M, Zhuge J, Zhong M and Liu
D: B-Raf and the inhibitors: From bench to bedside. J Hematol
Oncol. 6:302013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao
Y, Piao Y, Liu J, Cheng W, Bi X, et al: Encorafenib (LGX818), a
potent BRAF inhibitor, induces senescence accompanied by autophagy
in BRAFV600E melanoma cells. Cancer Lett. 370:332–344. 2016.
View Article : Google Scholar
|
|
52
|
Tran B and Cohen MS: The discovery and
development of binimetinib for the treatment of melanoma. Expert
Opin Drug Discov. 15:745–754. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lee PA, Wallace E, Marlow A, Yeh T, Marsh
V, Anderson D, Woessner R, Hurley B, Lyssikatos J, Poch G, et al:
Abstract 2515: Preclinical Development of ARRY-162, A Potent and
Selective MEK 1/2 Inhibitor. Cancer Res. 70(8_suppl): 25152010.
View Article : Google Scholar
|
|
54
|
Dummer R, Ascierto PA, Gogas HJ, Arance A,
Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer
R, et al: Encorafenib plus binimetinib versus vemurafenib or
encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A
multicentre, open-label, randomised phase 3 trial. Lancet Oncol.
19:603–615. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gogas HJ, Flaherty KT, Dummer R, Ascierto
PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D,
Krajsova I, et al: Adverse events associated with encorafenib plus
binimetinib in the COLUMBUS study: incidence, course and
management. Eur J Cancer. 119:97–106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Piscitelli J, Reddy MB, Wollenberg L, Del
Frari L, Gong J, Matschke K and Williams JH: Evaluation of the
effect of modafinil on the pharmacokinetics of encorafenib and
binimetinib in patients with BRAF V600-mutant advanced solid
tumors. Cancer Chemother Pharmacol. 94:337–347. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Delord JP, Robert C, Nyakas M, McArthur
GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford
RF, et al: Phase I dose-escalation and -expansion study of the BRAF
inhibitor encorafenib (LGX818) in metastatic BRAF-Mutant melanoma.
Clin Cancer Res. 23:5339–5348. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Adelmann CH, Ching G, Du L, Saporito RC,
Bansal V, Pence LJ, Liang R, Lee W and Tsai KY: Comparative
profiles of BRAF inhibitors: The paradox index as a predictor of
clinical toxicity. Oncotarget. 7:30453–30460. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Rambow F, Marine JC and Goding CR:
Melanoma plasticity and phenotypic diversity: Therapeutic barriers
and opportunities. Genes Dev. 33:1295–1318. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rubanov A, Berico P and Hernando E:
Epigenetic mechanisms underlying melanoma resistance to immune and
targeted therapies. Cancers (Basel). 14:58582022. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Alkaraki A, McArthur GA, Sheppard KE and
Smith LK: Metabolic plasticity in melanoma progression and response
to oncogene targeted therapies. Cancers (Basel). 13:58102021.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kakadia S, Yarlagadda N, Awad R, Kundranda
M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M and Mahmoud F:
Mechanisms of resistance to BRAF and MEK inhibitors and clinical
update of US Food and Drug Administration-approved targeted therapy
in advanced melanoma. Onco Targets Ther. 11:7095–7107. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Kemper K, de Goeje PL, Peeper DS and van
Amerongen R: Phenotype switching: Tumor cell plasticity as a
resistance mechanism and target for therapy. Cancer Res.
74:5937–5941. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Bai X, Fisher DE and Flaherty KT:
Cell-state dynamics and therapeutic resistance in melanoma from the
perspective of MITF and IFNү pathways. Nat Rev Clin Oncol.
16:549–562. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Konieczkowski DJ, Johannessen CM,
Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT,
Barzily-Rokni M, Straussman R, Haq R, et al: A melanoma cell state
distinction influences sensitivity to MAPK pathway inhibitors.
Cancer Discov. 4:816–827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Smith MP, Ferguson J, Arozarena I, Hayward
R, Marais R, Chapman A, Hurlstone A and Wellbrock C: Effect of
SMURF2 targeting on susceptibility to MEK inhibitors in melanoma. J
Natl Cancer Inst. 105:33–46. 2013. View Article : Google Scholar :
|
|
67
|
Smith MP, Brunton H, Rowling EJ, Ferguson
J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque
MP, et al: Inhibiting drivers of non-mutational drug tolerance is a
salvage strategy for targeted melanoma therapy. Cancer Cell.
29:270–284. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Rambow F, Rogiers A, Marin-Bejar O, Aibar
S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, DebiecRychter
M, et al: Toward minimal residual disease-directed therapy in
melanoma. Cell. 174:843–855.e19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Muller J, Krijgsman O, Tsoi J, Robert L,
Hugo W, Song C, Kong X, Possik PA, Cornelissen-Steijger PD, Geukes
Foppen MH, et al: Low MITF/AXL ratio predicts early resistance to
multiple targeted drugs in melanoma. Nat Commun. 5:57122014.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Marin-Bejar O, Rogiers A, Dewaele M, Femel
J, Karras P, Pozniak J, Bervoets G, Van Raemdonck N, Pedri D,
Swings T, et al: Evolutionary predictability of genetic versus
nongenetic resistance to anticancer drugs in melanoma. Cancer Cell.
39:1135–1149.e8. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Tsoi J, Robert L, Paraiso K, Galvan C,
Sheu KM, Lay J, Wong DJL, Atefi M, Shirazi R, Wang X, et al:
Multi-stage differentiation defines melanoma subtypes with
differential vulnerability to drug-induced iron-dependent oxidative
stress. Cancer Cell. 33:890–904.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Karras P, Bordeu I, Pozniak J, Nowosad A,
Pazzi C, Van Raemdonck N, Landeloos E, Van Herck Y, Pedri D,
Bervoets G, et al: A cellular hierarchy in melanoma uncouples
growth and metastasis. Nature. 610:190–198. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Boshuizen J, Koopman LA, Krijgsman O,
Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper
K, Kuilman T, Song JY, et al: Cooperative targeting of melanoma
heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK
inhibitors. Nat Med. 24:203–212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wouters J, Kalender-Atak Z, Minnoye L,
Spanier KI, De Waegeneer M, Bravo Gonzalez-Blas C, Mauduit D, Davie
K, Hulselmans G, Najem A, et al: Robust gene expression programs
underlie recurrent cell states and phenotype switching in melanoma.
Nat Cell Biol. 22:986–998. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Aiello-Couzo NM and Kang Y: A bridge
between melanoma cell states. Nat Cell Biol. 22:913–914. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Kim S, Carvajal R, Kim M and Yang HW:
Kinetics of RTK activation determine ERK reactivation and
resistance to dual BRAF/MEK inhibition in melanoma. Cell Rep.
42:1125702023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhou J, Chai X, Zhu Y, Huang Z, Lin T, Hu
Z, Chen G, Luo C, Cui R and Sheng J: A methyl-to-acetyl switch in
H3K27 drives metabolic reprogramming and resistance to BRAF(V600E)
inhibition in melanoma. Neoplasia. 68:1012232025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Torrano J, Al Emran A, Hammerlindl H and
Schaider H: Emerging roles of H3K9me3, SETDB1 and SETDB2 in
therapy-induced cellular reprogramming. Clin Epigenetics.
11:432019. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Roesch A, Vultur A, Bogeski I, Wang H,
Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA,
Philipp SE, et al: Overcoming intrinsic multidrug resistance in
melanoma by blocking the mitochondrial respiratory chain of
slow-cycling JARID1B(high) cells. Cancer Cell. 23:811–825. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Shen D, Zhang L, Li S and Tang L:
Metabolic reprogramming in melanoma therapy. Cell Death Discov.
11:3082025. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhao X, Chen F and Li H: Metabolic
reprogramming-a breakthrough point in overcoming resistance to BRAF
mutant melanoma targeted therapy (Review). Oncol Lett. 31:1842026.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Smith LK, Parmenter T, Kleinschmidt M,
Kusnadi EP, Kang J, Martin CA, Lau P, Patel R, Lorent J, Papadopoli
D, et al: Adaptive translational reprogramming of metabolism limits
the response to targeted therapy in BRAF(V600) melanoma. Nat
Commun. 13:11002022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Aloia A, Müllhaupt D, Chabbert CD,
Eberhart T, Flückiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A,
Alexander LT, Scibona E, et al: A fatty acid oxidation-dependent
metabolic shift regulates the adaptation of BRAF-mutated melanoma
to MAPK inhibitors. Clin Cancer Res. 25:6852–6867. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Wang J, Yao Z, Jonsson P, Allen AN, Qin
ACR, Uddin S, Dunkel IJ, Petriccione M, Manova K, Haque S, et al: A
secondary mutation in BRAF confers resistance to RAF inhibition in
a BRAF(V600E)-Mutant brain tumor. Cancer Discov. 8:1130–1141. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hoogstraat M, Gadellaa-van Hooijdonk CG,
Ubink I, Besselink NJ, Pieterse M, Veldhuis W, van Stralen M,
Meijer EF, Willems SM, Hadders MA, et al: Detailed imaging and
genetic analysis reveal a secondary 505H resistance mutation and
extensive intrapatient heterogeneity in metastatic mutant melanoma
patients treated with vemurafenib. Pigment Cell Melanoma Res.
28:318–323. 2015. View Article : Google Scholar
|
|
87
|
Wagenaar TR, Ma L, Roscoe B, Park SM,
Bolon DN and Green MR: Resistance to vemurafenib resulting from a
novel mutation in the BRAFV600E kinase domain. Pigment Cell
Melanoma Res. 27:124–133. 2014. View Article : Google Scholar
|
|
88
|
Arkenau HT, Kefford R and Long GV:
Targeting BRAF for patients with melanoma. Br J Cancer.
104:392–398. 2011. View Article : Google Scholar
|
|
89
|
Shi H, Moriceau G, Kong X, Lee MK, Lee H,
Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, et al: Melanoma
whole-exome sequencing identifies (V600E)B-RAF
amplification-mediated acquired B-RAF inhibitor resistance. Nat
Commun. 3:7242012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Villanueva J, Infante JR, Krepler C,
Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M,
Vultur A, et al: Concurrent MEK2 mutation and BRAF amplification
confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep.
4:1090–1099. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Rizos H, Menzies AM, Pupo GM, Carlino MS,
Fung C, Hyman J, Haydu LE, Mijatov B, Becker TM, Boyd SC, et al:
BRAF inhibitor resistance mechanisms in metastatic melanoma:
Spectrum and clinical impact. Clin Cancer Res. 20:1965–1977. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Shi H, Hugo W, Kong X, Hong A, Koya RC,
Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al:
Acquired resistance and clonal evolution in melanoma during BRAF
inhibitor therapy. Cancer Discov. 4:80–93. 2014. View Article : Google Scholar :
|
|
93
|
Poulikakos PI, Persaud Y, Janakiraman M,
Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al:
RAF inhibitor resistance is mediated by dimerization of aberrantly
spliced BRAF(V600E). Nature. 480:387–390. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Aya F, Lanuza-Gracia P, González-Pérez A,
Bonnal S, Mancini E, López-Bigas N, Arance A and Valcárcel J:
Genomic deletions explain the generation of alternative BRAF
isoforms conferring resistance to MAPK inhibitors in melanoma. Cell
Rep. 43:1140482024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Botton T, Talevich E, Mishra VK, Zhang T,
Shain AH, Berquet C, Gagnon A, Judson RL, Ballotti R, Ribas A, et
al: Genetic heterogeneity of BRAF fusion kinases in melanoma
affects drug responses. Cell Rep. 29:573–588.e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kulkarni A, Al-Hraishawi H, Simhadri S,
Hirshfield KM, Chen S, Pine S, Jeyamohan C, Sokol L, Ali S, Teo ML,
et al: BRAF fusion as a novel mechanism of acquired resistance to
vemurafenib in BRAF(V600E) mutant melanoma. Clin Cancer Res.
23:5631–5638. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Villanueva J, Vultur A, Lee JT,
Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu
X, Gimotty PA, Kee D, et al: Acquired resistance to BRAF inhibitors
mediated by a RAF kinase switch in melanoma can be overcome by
cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18:683–695. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Lu H, Villafane N, Dogruluk T, Grzeskowiak
CL, Kong K, Tsang YH, Zagorodna O, Pantazi A, Yang L, Neill NJ, et
al: Engineering and functional characterization of fusion genes
identifies novel oncogenic drivers of cancer. Cancer Res.
77:3502–3512. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Vojnic M, Kubota D, Kurzatkowski C, Offin
M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT,
Rudin CM, et al: Acquired BRAF rearrangements induce secondary
resistance to EGFR therapy in EGFR-Mutated lung cancers. J Thorac
Oncol. 14:802–815. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sase H, Nakanishi Y, Aida S,
Horiguchi-Takei K, Akiyama N, Fujii T, Sakata K, Mio T, Aoki M and
Ishii N: Acquired JHDM1D-BRAF fusion confers resistance to FGFR
inhibition in FGFR2-amplified gastric cancer. Mol Cancer Ther.
17:2217–2225. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zhang Y, Zhang X, Shao W, Gao J, Xiang M,
Wang Y, Liu M, Zhang W and Liang X: MEK inhibitors for the
treatment of immunotherapy-resistant, AGK-BRAF fusion advanced
acral melanoma: A case report and literature review. J Cancer Res
Clin Oncol. 151:1332025. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Wheler J, Yelensky R, Falchook G, Kim KB,
Hwu P, Tsimberidou AM, Stephens PJ, Hong D, Cronin MT and Kurzrock
R: Next generation sequencing of exceptional responders with
BRAF-mutant melanoma: Implications for sensitivity and resistance.
BMC Cancer. 15:612015. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wagle N, Van Allen EM, Treacy DJ,
Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM,
Sullivan RJ, Farlow DN, et al: MAP kinase pathway alterations in
BRAF-mutant melanoma patients with acquired resistance to combined
RAF/MEK inhibition. Cancer Discov. 4:61–68. 2014. View Article : Google Scholar :
|
|
104
|
Long GV, Fung C, Menzies AM, Pupo GM,
Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP,
et al: Increased MAPK reactivation in early resistance to
dabrafenib/trametinib combination therapy of BRAF-mutant metastatic
melanoma. Nat Commun. 5:56942014. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Emery CM, Vijayendran KG, Zipser MC,
Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA,
Karpova MB, et al: MEK1 mutations confer resistance to MEK and
B-RAF inhibition. Proc Natl Acad Sci USA. 106:20411–20416. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Nikolaev SI, Rimoldi D, Iseli C, Valsesia
A, Robyr D, Gehrig C, Harshman K, Guipponi M, Bukach O, Zoete V, et
al: Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2
mutations in melanoma. Nat Genet. 44:133–139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Irvine M, Stewart A, Pedersen B, Boyd S,
Kefford R and Rizos H: Oncogenic PI3K/AKT promotes the step-wise
evolution of combination BRAF/MEK inhibitor resistance in melanoma.
Oncogenesis. 7:72–83. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Candido S, Salemi R, Piccinin S, Falzone L
and Libra M: The PIK3CA H1047R mutation confers resistance to BRAF
and MEK inhibitors in A375 melanoma cells through the
cross-activation of MAPK and PI3K-Akt pathways. Pharmaceutics.
14:5902022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Jazirehi AR, Wenn PB and Damavand M:
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR
signaling module in melanoma therapy. Am J Cancer Res. 2:178–191.
2012.PubMed/NCBI
|
|
110
|
Orgaz JL, Crosas-Molist E, Sadok A,
Perdrix-Rosell A, Maiques O, Rodriguez-Hernandez I, Monger J, Mele
S, Georgouli M, Bridgeman V, et al: Myosin II reactivation and
cytoskeletal remodeling as a hallmark and a vulnerability in
melanoma therapy resistance. Cancer Cell. 37:85–103.e9. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Misek SA, Appleton KM, Dexheimer TS,
Lisabeth EM, Lo RS, Larsen SD, Gallo KA and Neubig RR: Rho-mediated
signaling promotes BRAF inhibitor resistance in de-differentiated
melanoma cells. Oncogene. 39:1466–1483. 2020. View Article : Google Scholar :
|
|
112
|
Babagana M, Johnson S, Slabodkin H, Bshara
W, Morrison C and Kandel ES: P21-activated kinase 1 regulates
resistance to BRAF inhibition in human cancer cells. Mol Carcinog.
56:1515–1525. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Yun CY, You ST, Kim JH, Chung JH, Han SB,
Shin EY and Kim EG: p21-activated kinase 4 critically regulates
melanogenesis via activation of the CREB/MITF and β-catenin/MITF
pathways. J Invest Dermatol. 135:1385–1394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y,
Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, et al: PAK
signalling drives acquired drug resistance to MAPK inhibitors in
BRAF-mutant melanomas. Nature. 550:133–136. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Sankaran D, Amjesh R, Paul AM, George B,
Kala R, Saini S and Kumar R: Hyperactivation of p21-activated
kinases in human cancer and therapeutic sensitivity. Biomedicines.
11:4622023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Wu M, Hanly A, Gibson F, Fisher R, Rogers
S, Park K, Zuger A, Kuang K, Kalin JH, Nocco S, et al: The CoREST
repressor complex mediates phenotype switching and therapy
resistance in melanoma. J Clin Invest. 134:e1716032024. View Article : Google Scholar
|
|
117
|
Hong X, Roh W, Sullivan RJ, Wong KHK,
Wittner BS, Guo H, Dubash TD, Sade-Feldman M, Wesley B, Horwitz E,
et al: The lipogenic regulator SREBP2 induces transferrin in
circulating melanoma cells and suppresses ferroptosis. Cancer
Discov. 11:678–695. 2021. View Article : Google Scholar :
|
|
118
|
Sanchez-Hernandez I, Baquero P, Calleros L
and Chiloeches A: Dual inhibition of (V600E)BRAF and the
PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma
cells through a MEK-independent mechanism. Cancer Lett.
314:244–255. 2012. View Article : Google Scholar
|
|
119
|
Dummer R, Sandhu S, Miller WH Jr, Butler
MO, Taylor MH, Heinzerling L, Blank CU, Muñoz-Couselo E, Burris HA
III, Postow MA, et al: Longitudinal genomic analysis to fine-tune
targeted therapy: Results of the phase II LOGIC 2 trial in patients
with BRAFV600-Mutant metastatic melanoma. Clin Cancer Res.
31:2097–2107. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Kim KB, Desprez PY, de Semir D, Woo RWL,
Sharma A, Jones R, Caressi C, Nosrati M, Janiczek E, Rivera
Penafiel J and Kashani-Sabet M: Phase II study of niraparib in
patients with advanced melanoma with homologous recombination
pathway gene mutations. JCO Precis Oncol. 9:e24006582025.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Algazi AP, Moon J, Lao CD, Chmielowski B,
Kendra KL, Lewis KD, Gonzalez R, Kim K, Godwin JE, Curti BD, et al:
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT
inhibitors for patients with BRAF-mutated cancers. Cancer.
130:1784–1796. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Paraiso KH, Haarberg HE, Wood E, Rebecca
VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, et al:
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance
mediated through diverse mechanisms. Clin Cancer Res. 18:2502–2514.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Eroglu Z, Chen YA, Smalley I, Li J,
Markowitz JK, Brohl AS, Tetteh L, Taylor H, Sondak VK, Khushalani
NI and Smalley KSM: Combined BRAF, MEK, and heat-shock protein 90
inhibition in advanced BRAF V600-mutant melanoma. Cancer.
130:232–243. 2024. View Article : Google Scholar
|
|
124
|
Ascierto PA, Casula M, Bulgarelli J,
Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF,
Guidoboni M, et al: Sequential immunotherapy and targeted therapy
for metastatic BRAF V600 mutated melanoma: 4-year survival and
biomarkers evaluation from the phase II SECOMBIT trial. Nat Commun.
15:1462024. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Atkins MB, Lee SJ, Chmielowski B, Tarhini
AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson
JJ, et al: Combination dabrafenib and trametinib versus combination
nivolumab and ipilimumab for patients with advanced BRAF-Mutant
melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol.
41:186–197. 2023. View Article : Google Scholar :
|
|
126
|
Wang T, Xiao M, Ge Y, Krepler C, Belser E,
Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, et al: BRAF
inhibition stimulates melanoma-associated macrophages to drive
tumor growth. Clin Cancer Res. 21:1652–1664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Hu-Lieskovan S, Mok S, Homet Moreno B,
Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG,
Comin-Anduix B and Ribas A: Improved antitumor activity of
immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Sci Transl Med. 7:279ra412015. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Buchbinder EI, Giobbie-Hurder A, Haq R and
Ott PA: A phase I/II study of LY3022855 with BRAF/MEK inhibition in
patients with Melanoma. Invest New Drugs. 41:551–555. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Buchbinder EI, Giobbie-Hurder A and Ott
PA: A phase I/II study of MCS110 with BRAF/MEK inhibition in
patients with melanoma after progression on BRAF/MEK inhibition.
Invest New Drugs. 41:365–370. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Samarkina A, Youssef MK, Ostano P, Ghosh
S, Ma M, Tassone B, Proust T, Chiorino G, Levesque MP, Goruppi S
and Dotto GP: Androgen receptor is a determinant of melanoma
targeted drug resistance. Nat Commun. 14:64982023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Grant C, Ewart L, Muthas D, Deavall D,
Smith SA, Clack G and Newham P: The value of integrating
pre-clinical data to predict nausea and vomiting risk in humans as
illustrated by AZD3514, a novel androgen receptor modulator.
Toxicol Appl Pharmacol. 296:10–18. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Omlin A, Jones RJ, van der Noll R, Satoh
T, Niwakawa M, Smith SA, Graham J, Ong M, Finkelman RD, Schellens
JH, et al: AZD3514, an oral selective androgen receptor
down-regulator in patients with castration-resistant prostate
cancer-results of two parallel first-in-human phase I studies.
Invest New Drugs. 33:679–690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Loftus AW, Zarei M, Kakish H, Hajihassani
O, Hue JJ, Boutros C, Graor HJ, Nakazzi F, Bahlibi T, Winter JM and
Rothermel LD: Therapeutic implications of the metabolic changes
associated with BRAF inhibition in melanoma. Cancer Treat Rev.
129:1027952024. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Vashisht Gopal YN, Gammon S, Prasad R,
Knighton B, Pisaneschi F, Roszik J, Feng N, Johnson S, Pramanik S,
Sudderth J, et al: A novel mitochondrial inhibitor blocks MAPK
pathway and overcomes MAPK inhibitor resistance in melanoma. Clin
Cancer Res. 25:6429–6442. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Audrito V, Managò A, La Vecchia S,
Zamporlini F, Vitale N, Baroni G, Cignetto S, Serra S, Bologna C,
Stingi A, et al: Nicotinamide phosphoribosyltransferase (NAMPT) as
a therapeutic target in BRAF-Mutated metastatic melanoma. J Natl
Cancer Inst. 110:2018. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Baenke F, Chaneton B, Smith M, Van Den
Broek N, Hogan K, Tang H, Viros A, Martin M, Galbraith L, Girotti
MR, et al: Resistance to BRAF inhibitors induces glutamine
dependency in melanoma cells. Mol Oncol. 10:73–84. 2016. View Article : Google Scholar
|
|
137
|
Hernandez-Davies JE, Tran TQ, Reid MA,
Rosales KR, Lowman XH, Pan M, Moriceau G, Yang Y, Wu J, Lo RS and
Kong M: Vemurafenib resistance reprograms melanoma cells towards
glutamine dependence. J Transl Med. 13:2102015. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wang L, Leite de Oliveira R, Huijberts S,
Bosdriesz E, Pencheva N, Brunen D, Bosma A, Song JY, Zevenhoven J,
Los-de Vries GT, et al: An acquired vulnerability of drug-resistant
melanoma with therapeutic potential. Cell. 173:1413–1425.e14. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI
|
|
140
|
Robert C, Kicinski M, Dutriaux C, Routier
É, Govaerts AS, Bührer E, Neidhardt EM, Durando X, Baroudjian B,
Saiag P, et al: Combination of encorafenib and binimetinib followed
by ipilimumab and nivolumab versus ipilimumab and nivolumab in
patients with advanced melanoma with BRAF(V600E) or BRAF(V600K)
mutations (EBIN): An international, open-label, randomised,
controlled, phase 2 study. Lancet Oncol. 26:781–794. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Trojaniello C, Sparano F, Cioli E and
Ascierto PA: Sequencing targeted and immune therapy in BRAF-Mutant
melanoma: Lessons learned. Curr Oncol Rep. 25:623–634. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Dummer R, Welti M and Ramelyte E: The role
of triple therapy and therapy sequence in treatment of BRAF-mutant
metastatic melanoma. Response to overall survival with first-line
atezolizumab in combination with vemurafenib and cobimetinib in
BRAFV600 mutation-positive advanced melanoma (IMspire150): Second
interim analysis of a multicentre, randomised, phase 3 study. J
Transl Med. 21:5292023. View Article : Google Scholar
|
|
143
|
Ascierto PA, Mandalà M, Ferrucci PF,
Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello
E, Gogas H, et al: Sequencing of ipilimumab plus nivolumab and
encorafenib plus binimetinib for untreated BRAF-Mutated metastatic
melanoma (SECOMBIT): A Randomized, three-arm, open-label phase II
trial. J Clin Oncol. 41:212–221. 2023. View Article : Google Scholar
|
|
144
|
Ascierto PA, Mandalà M, Ferrucci PF,
Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello
E, Gogas H, et al: Sequencing of checkpoint or BRAF/MEK inhibitors
on brain metastases in melanoma. NEJM Evid. 3:EVIDoa24000872024.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Patel RP, Saleh R, Lim LRJ, Rao AD, Smith
L, Trigos A, Haynes NM, McArthur GA and Sheppard KE: BRAF/MEK
inhibition following immune checkpoint inhibitors promotes
antitumor immunity associated with expansion of
progenitor-exhausted CD8+ T cells. EJC Skin Cancer.
3:1007372025. View Article : Google Scholar
|
|
146
|
Kopecký J, Pásek M, Lakomý R, Melichar B,
Mrazová I, Kubeček O, Arenbergerová M, Lemstrová R, Švancarová A,
Tretera V, et al: The outcome in patients with BRAF-mutated
metastatic melanoma treated with anti-programmed death receptor-1
monotherapy or targeted therapy in the real-world setting. Cancer
Med. 13:e69822024. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Boutros A, Croce E, Ferrari M, Gili R,
Massaro G, Marconcini R, Arecco L, Tanda ET and Spagnolo F: The
treatment of advanced melanoma: Current approaches and new
challenges. Crit Rev Oncol Hematol. 196:1042762024. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Haas L, Elewaut A, Gerard CL, Umkehrer C,
Leiendecker L, Pedersen M, Krecioch I, Hoffmann D, Novatchkova M,
Kuttke M, et al: Acquired resistance to anti-MAPK targeted therapy
confers an immune-evasive tumor microenvironment and
cross-resistance to immunotherapy in melanoma. Nat Cancer.
2:693–708. 2021. View Article : Google Scholar
|
|
149
|
Ferrucci PF, Di Giacomo AM, Del Vecchio M,
Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Stephens
R, Svane IM, et al: KEYNOTE-022 part 3: A randomized, double-blind,
phase 2 study of pembrolizumab, dabrafenib, and trametinib in
BRAF-mutant melanoma. J Immunother Cancer. 8:e0018062020.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Ascierto PA, Ferrucci PF, Fisher R, Del
Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV,
Di Giacomo AM, et al: Dabrafenib, trametinib and pembrolizumab or
placebo in BRAF-mutant melanoma. Nat Med. 25:941–946. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Albrecht LJ, Dimitriou F, Grover P, Hassel
JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke
JM, et al: Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy)
after failure of immune checkpoint inhibition and targeted therapy
in patients with advanced melanoma. Eur J Cancer. 202:1139762024.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Dixon-Douglas JR, Patel RP, Somasundram PM
and McArthur GA: Triplet therapy in melanoma-combined BRAF/MEK
inhibitors and anti-PD-(L)1 antibodies. Curr Oncol Rep.
24:1071–1079. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Pozniak J, Pedri D, Landeloos E, Van Herck
Y, Antoranz A, Vanwynsberghe L, Nowosad A, Roda N, Makhzami S,
Bervoets G, et al: A TCF4-dependent gene regulatory network confers
resistance to immunotherapy in melanoma. Cell. 187:166–183.e25.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Lim SY, Shklovskaya E, Lee JH, Pedersen B,
Stewart A, Ming Z, Irvine M, Shivalingam B, Saw RPM, Menzies AM, et
al: The molecular and functional landscape of resistance to immune
checkpoint blockade in melanoma. Nat Commun. 14:15162023.
View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Thornton J, Chhabra G, Singh CK,
Guzman-Perez G, Shirley CA and Ahmad N: Mechanisms of immunotherapy
resistance in cutaneous melanoma: Recognizing a shapeshifter. Front
Oncol. 12:8808762022. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Hieken TJ, Nelson GD, Flotte TJ, Grewal
EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay
E, Dronca RS, et al: Neoadjuvant cobimetinib and atezolizumab with
or without vemurafenib for high-risk operable stage III melanoma:
The phase II NeoACTIVATE trial. Nat Commun. 15:14302024. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Block MS, Nelson GD, Chen J, Johnson S,
Yang L, Flotte TJ, Grewal EP, McWilliams RR, Kottschade LA,
Domingo-Musibay E, et al: Neoadjuvant cobimetinib and atezolizumab
with or without vemurafenib for stage III melanoma: Outcomes and
the impact of the microbiome from the NeoACTIVATE trial. J
Immunother Cancer. 13:e0117062025. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Long GV, Carlino MS, Au-Yeung G, Spillane
AJ, Shannon KF, Gyorki DE, Hsiao E, Kapoor R, Thompson JR, Batula
I, et al: Neoadjuvant pembrolizumab, dabrafenib and trametinib in
BRAF(V600)-mutant resectable melanoma: The randomized phase 2
NeoTrio trial. Nat Med. 30:2540–2548. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Dudnichenko O, Penkov K, McKean M, Mandalà
M, Kukushkina M, Panella T, Csőszi T, Gerletti P, Thakur M, Polli
A, et al: First-line encorafenib plus binimetinib and pembrolizumab
for advanced BRAF V600-mutant melanoma: Safety lead-in results from
the randomized phase III STARBOARD study. Eur J Cancer.
213:1150702024. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Chapman PB, Klang M, Postow MA, Shoushtari
AN, Sullivan RJ, Wolchok JD, Merghoub T, Budhu S, Wong P, Callahan
MK, et al: Phase Ib trial of phenformin in patients with
V600-mutated melanoma receiving dabrafenib and trametinib. Cancer
Res Commun. 3:2447–2454. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo
C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC and Zheng
B: Phenformin enhances the therapeutic benefit of BRAF(V600E)
inhibition in melanoma. Proc Natl Acad Sci USA. 110:18226–18231.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ren L, Moreno D, Baer BR, Barbour P,
Bettendorf T, Bouhana K, Brown K, Brown SA, Fell JB, Hartley DP, et
al: Identification of the clinical candidate PF-07284890
(ARRY-461), a highly potent and brain penetrant BRAF inhibitor for
the treatment of cancer. J Med Chem. 67:13019–13032. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Mandalà M, Palmieri G, Ludovini V, Baglivo
S, Marasciulo F, Castiglione F, Gili A, Osella Abate S, Rubatto M,
Senetta R, et al: BRAFV600 variant allele frequency predicts
outcome in metastatic melanoma patients treated with BRAF and MEK
inhibitors. J Eur Acad Dermatol Venereol. 37:1991–1998. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Guida M, Apollonio B, Romano L, Spagnolo
F, Quaglino P, Depenni R, Pinto R, Squicciarini T, Fucci L, Di
Tullio P, et al: High BRAF variant allele frequency predicts poor
outcomes in metastatic melanoma patients treated with BRAF/MEK
inhibitors. J Transl Med. 23:14072025. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Mattila KE, Mäkelä S, Kytölä S, Andersson
E, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS,
Tyynelä-Korhonen K, et al: Circulating tumor DNA is a prognostic
biomarker in metastatic melanoma patients treated with
chemoimmunotherapy and BRAF inhibitor. Acta Oncol. 61:1263–1267.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Stadler JC, Belloum Y, Deitert B,
Sementsov M, Heidrich I, Gebhardt C, Keller L and Pantel K: Current
and future clinical applications of ctDNA in immuno-oncology.
Cancer Res. 82:349–358. 2022. View Article : Google Scholar
|
|
167
|
Syeda MM, Long GV, Garrett J, Atkinson V,
Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M,
Chiarion-Sileni V, et al: Clinical validation of droplet digital
PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as
a prognostic biomarker in patients with resected stage III melanoma
receiving adjuvant therapy (COMBI-AD): A biomarker analysis from a
double-blind, randomised phase 3 trial. Lancet Oncol. 26:641–653.
2025. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Gassenmaier M, Lenders MM, Forschner A,
Leiter U, Weide B, Garbe C, Eigentler TK and Wagner NB: Serum S100B
and LDH at baseline and during therapy predict the outcome of
metastatic melanoma patients treated with BRAF inhibitors. Target
Oncol. 16:197–205. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Arozarena I and Wellbrock C: Phenotype
plasticity as enabler of melanoma progression and therapy
resistance. Nat Rev Cancer. 19:377–391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Ribas A, Kim KB, Schuchter LM, Gonzalez R,
Pavlick AC, Weber JS, McArthur GA, Hutson TE, Flaherty KT and
Moschos SJ: BRIM-2: An open-label, multicenter phase II study of
vemurafenib in previously treated patients with BRAFV600E
mutation-positive metastatic melanoma. J Clin Oncol. 29(15_suppl):
85092011. View Article : Google Scholar
|
|
171
|
Falchook GS, Long GV, Kurzrock R, Kim KB,
Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC,
et al: Dabrafenib in patients with melanoma, untreated brain
metastases, and other solid tumours: A phase 1 dose-escalation
trial. Lancet. 379:1893–1901. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Long GV, Trefzer U, Davies MA, Kefford RF,
Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi
A, et al: Dabrafenib in patients with Val600Glu or Val600Lys
BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A
multicentre, open-label, phase 2 trial. Lancet Oncol. 13:1087–1095.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Infante JR, Fecher LA, Falchook GS,
Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y,
Morris SR, et al: Safety, pharmacokinetic, pharmacodynamic, and
efficacy data for the oral MEK inhibitor trametinib: A phase 1
dose-escalation trial. Lancet Oncol. 13:773–781. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Davies MA, Saiag P, Robert C, Grob JJ,
Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T,
Mortier L, et al: Dabrafenib plus trametinib in patients with
BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): A
multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol.
18:863–873. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Long GV, Hauschild A, Santinami M,
Atkinson V, Mandala M, Chiarion-Sileni V, Larkin J, Nyakas M,
Dutriaux C, Haydon A, et al: Adjuvant dabrafenib plus trametinib in
stage III BRAF-Mutated melanoma. N Engl J Med. 377:1813–1823. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Ribas A, Gonzalez R, Pavlick A, Hamid O,
Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K,
et al: Combination of vemurafenib and cobimetinib in patients with
advanced BRAF(V600)-mutated melanoma: A phase 1b study. Lancet
Oncol. 15:954–965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Yee MK, Lin Y, Gorantla VC, Butterfield
LH, Kluger HM, Chapman PB, Gangadhar TC, Milhem MM, Pavlick AC,
Amaravadi RK, et al: Phase 2 study of cobimetinib in combination
with vemurafenib in active melanoma brain metastases (coBRIM-B). J
Clin Oncol. 33(15_suppl): TPS90882015. View Article : Google Scholar
|
|
179
|
Sullivan RJ, Weber J, Patel S, Dummer R,
Carlino MS, Tan DSW, Lebbé C, Siena S, Elez E, Wollenberg L, et al:
A Phase Ib/II study of the BRAF inhibitor encorafenib plus the MEK
inhibitor binimetinib in patients with BRAF(V600E/K) -mutant solid
tumors. Clin Cancer Res. 26:5102–5112. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Corradi G, De Martino S, Rinaldi A, Siepe
G, Marchese PV, Melotti B and Comito F: Rapid radiological response
of leptomeningeal carcinosis and prolonged survival to encorafenib
and binimetinib in BRAF-mutated melanoma. Anticancer Drugs.
36:691–693. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Falchook GS, Long GV, Kurzrock R, Kim KB,
Arkenau HT, Brown MP, Hamid O, Infante JR, Millward M, Pavlick A,
et al: Dose selection, pharmacokinetics, and pharmacodynamics of
BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res.
20:4449–4458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Long GV, Eroglu Z, Infante J, Patel S,
Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, et
al: Long-term outcomes in patients with BRAF V600-Mutant metastatic
melanoma who received dabrafenib combined with trametinib. J Clin
Oncol. 36:667–673. 2018. View Article : Google Scholar
|
|
183
|
Dummer R, Flaherty KT, Robert C, Arance A,
B de Groot JW, Garbe C, Gogas HJ, Gutzmer R, Krajsová I, Liszkay G,
et al: COLUMBUS 5-year update: A randomized, open-label, phase III
trial of encorafenib plus binimetinib versus vemurafenib or
encorafenib in patients with BRAF. Future Oncol. 19:1091–1098.
2023. View Article : Google Scholar : PubMed/NCBI
|
